Fig. 3: AIF in apoptosis and cell-survival pathway predicts response to MTI.
From: Predicting and affecting response to cancer therapy based on pathway-level biomarkers
a ‘AIF in apoptosis and cell-survival pathway’ activity levels in sensitive (blue) and not-sensitive (red) lung cancer cell lines in microarray and RNA-seq. Box plots represent the MTIs that were identified by this analysis across all lung cancer cell lines. Error bars represent the standard deviation. P-values were generated using Mann–Whitney U-test. b ROC analysis was constructed to evaluate the prognostic power of the AIF pathway versus the three pathway genes (AIF1, BCL-XL, PARP1) in the TCGA lung adenocarcinoma dataset. The AUC was used to quantify response prediction. c Box plot of BCL2-protein family member expression levels in sensitive (blue boxes) and not-sensitive (red boxes) cell lines. Error bars represent the standard deviation. d Validation sets of lung cancer cell lines25 and patients (TCGA) that were treated with MTIs. Box plots show AIF pathway activity levels in the sensitive and not-sensitive cell lines (left panel) as well as in patients with complete response or progressive disease (right panel). Error bars represent the standard deviation. P-values were generated using Mann–Whitney U-test. See also Supplementary Figs. 5, 6.
